Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public Shareholders

Audio By Carbonatix

MILWAUKEE--(BUSINESS WIRE)--Aug 8, 2025--

The Ademi Firm is investigating Y-mAbs (NASDAQ: YMAB) for possible breaches of fiduciary duty and other violations of law in its transaction with SERB Pharmaceuticals .

Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.

In the tender offer transaction, shareholders of Y-mAbs will receive $ $8.60 per share in cash, representing approximately $412 million in equity value. Y-mAbs insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for Y-mAbs by imposing a significant penalty if Y-mAbs accepts a competing bid. We are investigating the conduct of the Y-mAbs board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250808933548/en/

CONTACT: Ademi & Fruchter LLP

Guri Ademi

Toll Free: (866) 264-3995

Fax: (414) 482-8001

KEYWORD: UNITED STATES NORTH AMERICA WISCONSIN

INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL

SOURCE: Ademi & Fruchter LLP

Copyright Business Wire 2025.

PUB: 08/08/2025 08:22 AM/DISC: 08/08/2025 08:22 AM

http://www.businesswire.com/news/home/20250808933548/en